Cannabis Use Disorder, SevereICAENCT07746440

Impact of Cannabis Use and Abstinence on Emotion

A study testing Contingency management for cannabis abstinence and lab visit attendance and Contingency management for lab visit attendance in people with Cannabis Use Disorder, Severe, run by Florida State University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The goal of this experimental study is to test how three weeks of cannabis abstinence impacts threat and reward processing in females with Cannabis Use Disorder. The main questions it aims to answer are: Compared to using cannabis as usual, will cannabis cue reactivity increase throughout three weeks of abstinence… Read more about this study

Who is it for?: Ages 18 to 30 years, women only
Conditions the study is for: Cannabis Use Disorder, Severe
What is being tested?: Contingency management for cannabis abstinence and lab visit attendance and Contingency management for lab visit attendance
Type of treatment: Lifestyle or therapy programme
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 30 participants
Where: 1 siteUnited States
Study dates: 24 Jan 2022to 15 Jul 2024
Phase: Interventional
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 30 years
Women only
No healthy volunteers
Adult

Who may be able to join

>=5 cannabis use days per week on average over the past 3 months
Female
>=6 past-year CUD symptoms (must include withdrawal and at least one criterion other than craving must be met within the past 3 months)
>=20 days of cannabis use over the past 30 days
Positive urinalysis for THC
Cannabis is primary substance of abuse

Who cannot join

Current pregnancy
History of psychotic, seizure, or cardiovascular disorder
Immediate plan to quit cannabis
Current treatment for cannabis use
Current daily psychotropic medication use
Lotion allergy

Show all 10Show fewer

Positive urinalysis for any drug other than THC
CSRSS >= 4
Current moderate (4+ criteria) or severe (6+ criteria) substance use disorder (SUD) other than CUD or nicotine dependence
CBD use >= 9 days

Trial locations and contacts

1 site in 1 country.

United States1 site

The BRAINS Lab in the Department of Psychology at Florida State University
Tallahassee, Florida, 32304

Other trials in United States

About this study

Official title: Impact of Cannabis Withdrawal and Early Abstinence on Threat and Reward Processing

Compared to using cannabis as usual, will cannabis cue reactivity increase throughout three weeks of abstinence from cannabis?

Compared to using cannabis as usual, will threat reactivity be elevated at weeks 1 and 2 of abstinence followed by a decrease at week 3 of abstinence?

Compared to using cannabis as usual, will non-drug reward reactivity be lower at weeks 1 and 2 of abstinence followed by an increase at week 3 of abstinence?

Compared to successful 3-week abstainers, will threat, non-drug reward, and cannabis cue reactivity differ in relapsers?

Researchers will compare females with CUD who abstain from cannabis for three weeks to those who continue to use cannabis as usual to see how cannabis abstinence impacts threat and reward processing.

Participants will:

Be randomly assigned to continue using cannabis as usual or abstain from cannabis for three weeks Visit the lab 6 times over three weeks, followed by a 1-month follow-up lab visit for the participants assigned to the cannabis abstinence condition Complete phone surveys every other day across the three week study period

Conditions: Cannabis Use Disorder, Severe
Being tested: Contingency management for cannabis abstinence and lab visit attendance, Contingency management for lab visit attendance

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Contingency management for cannabis abstinence and lab visit attendanceBehavioural
Escalating monetary reinforcement is provided for continuous cannabis abstinence and lab visit attendance across the three week study period.
Contingency management for lab visit attendanceBehavioural
Escalating monetary reinforcement is provided for lab visit attendance across the three week study period.

Study groups in NCT07746440
Study group	Role	What they receive
Contingency Management for Cannabis Abstinence and Lab Visit Attendance	Experimental	Participants randomly assigned to this arm will receive contingency management for three weeks to reinforce sustained abstinence from cannabis and attendance at all lab visits. Receives: Behavioral: Contingency management for cannabis abstinence and lab visit attendance
Contingency Management for Lab Visit Attendance	Other	Participants randomly assigned to this arm will receive contingency management for three weeks to reinforce attendance at all lab visits. Participants will continue to use cannabis as usual. Receives: Behavioral: Contingency management for lab visit attendance

What is being measured

The primary outcome is the main question the study is designed to answer.

Late Positive Potential
The Late Positive Potential (neural measure recorded via electroencephalography) will be quantified from ~400 to 3000ms at central-parietal sensors relative to the onset of a cannabis, neutral, unpleasant, or pleasant image. The Late Positive Potential to cannabis vs. neutral and cannabis vs. pleasant will be the primary contrasts of interest.
Measured: Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up
Reward Positivity
The Reward Positivity (neural measure recorded via electroencephalography) will be quantified from ~200-300ms at frontal-central sensors relative to the onset of monetary win and loss feedback. The win vs. loss contrast will be the primary outcome of interest.
Measured: Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up
Eyeblink Startle Response
The Eyeblink Startle Response (recorded via EMG sensors) will be quantified as the peak blink amplitude relative to the onset of an auditory startle probe during blocks with predictable shocks, unpredictable shocks, and no threat of shock. The Eyeblink Startle Response during unpredictable shock threat vs. no shock threat will be the primary contrast of interest.
Measured: Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up

Secondary outcomes (2)

Delta Power
Delta Power (neural time-frequency measure recorded via electroencephalography) will be quantified as event-related spectral power from 1-3.5Hz at frontal-central sensors relative to the onset of monetary win and loss feedback. The win vs. loss contrast will be the primary outcome of interest.
Measured: Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up
Delta Intertrial Phase Coherence
Delta Intertrial Phase Coherence (neural time-frequency measure recorded via electroencephalography) will be quantified as intertrial phase coherence of 1-3.5Hz oscillations at frontal-central sensors relative to the onset of monetary win and loss feedback. The win vs. loss contrast will be the primary outcome of interest.
Measured: Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

24 Jan 202215 Jul 2024

First posted5 Aug 2026
Study start24 Jan 2022
Primary completion15 Jul 2024
Study completion15 Jul 2024

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Cannabis Use Disorder, SevereStudies of the same condition, open and under way.
More trials run by Florida State UniversityThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Basic science
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Enrolment: 30 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07746440
Sponsor's protocol ID: AUIRB#20-217FB
Acronym: ICAE
Status last verified: Jul 2026
First submitted: 30 Jul 2026
Last updated: 5 Aug 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Active, not recruitingPhase 2
Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study
Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
Not yet recruitingPhase 3
Tirzepatide in the Treatment of Cannabis Use Disorder
Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
Recruiting
Cannabis and Processing Emotions Study
Cannabis Use Disorder, Severe
Active, not recruiting
Cannabis Use Disorder Treatment Study
Cannabis Use Disorder, Mild, Cannabis Use Disorder, Moderate

All Cannabis Use Disorder, Severe trials

Study at a glance

From the registry record, last updated by the sponsor on 5 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Impact of Cannabis Withdrawal and Early Abstinence on Threat and Reward Processing
ClinicalTrials.gov ID: NCT07746440
Acronym / sponsor ID: ICAE / AUIRB#20-217FB
Conditions: Cannabis Use Disorder, Severe
Study type: Interventional
Recruitment status: Completed
Enrolment: 30 participants (actual)
Lead sponsor: Florida State UniversityUniversity, hospital or other
Collaborators: Auburn University
Study start: 24 Jan 2022 (actual)
Primary completion: 15 Jul 2024 (actual)
Study completion: 15 Jul 2024 (actual)
First posted: 5 Aug 2026 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Compared to using cannabis as usual, will cannabis cue reactivity increase throughout three weeks of abstinence from cannabis?

Compared to using cannabis as usual, will threat reactivity be elevated at weeks 1 and 2 of abstinence followed by a decrease at week 3 of abstinence?

Compared to using cannabis as usual, will non-drug reward reactivity be lower at weeks 1 and 2 of abstinence followed by an increase at week 3 of abstinence?

Compared to successful 3-week abstainers, will threat, non-drug reward, and cannabis cue reactivity differ in relapsers?

Researchers will compare females with CUD who abstain from cannabis for three weeks to those who continue to use cannabis as usual to see how cannabis abstinence impacts threat and reward processing.

Participants will:

Study design

Primary purpose: Basic science
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Number of arms: 2

Arm	Type	Receives
Contingency Management for Cannabis Abstinence and Lab Visit Attendance	Experimental	Behavioral: Contingency management for cannabis abstinence and lab visit attendanceParticipants randomly assigned to this arm will receive contingency management for three weeks to reinforce sustained abstinence from cannabis and attendance at all lab visits.
Contingency Management for Lab Visit Attendance	Other	Behavioral: Contingency management for lab visit attendanceParticipants randomly assigned to this arm will receive contingency management for three weeks to reinforce attendance at all lab visits. Participants will continue to use cannabis as usual.

Who may qualify

Ages: 18 to 30 years
Sex: Female only
Healthy volunteers: Not accepted
Age groups: Adult

Key inclusion criteria (6 listed)

>=5 cannabis use days per week on average over the past 3 months
Female
>=6 past-year CUD symptoms (must include withdrawal and at least one criterion other than craving must be met within the past 3 months)
>=20 days of cannabis use over the past 30 days
Positive urinalysis for THC

Key exclusion criteria (10 listed)

Current pregnancy
History of psychotic, seizure, or cardiovascular disorder
Immediate plan to quit cannabis
Current treatment for cannabis use
Current daily psychotropic medication use

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Contingency management for cannabis abstinence and lab visit attendanceEscalating monetary reinforcement is provided for continuous cannabis abstinence and lab visit attendance across the three week study period.	Behavioural	Contingency Management for Cannabis Abstinence and Lab Visit Attendance
Contingency management for lab visit attendanceEscalating monetary reinforcement is provided for lab visit attendance across the three week study period.	Behavioural	Contingency Management for Lab Visit Attendance

Primary outcome

Late Positive Potential
Time frame: Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up
The Late Positive Potential (neural measure recorded via electroencephalography) will be quantified from ~400 to 3000ms at central-parietal sensors relative to the onset of a cannabis, neutral, unpleasant, or pleasant image. The Late Positive Potential to cannabis vs. neutral and cannabis vs. pleasant will be the primary contrasts of interest.
Reward Positivity
Time frame: Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up
The Reward Positivity (neural measure recorded via electroencephalography) will be quantified from ~200-300ms at frontal-central sensors relative to the onset of monetary win and loss feedback. The win vs. loss contrast will be the primary outcome of interest.
Eyeblink Startle Response
Time frame: Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up
The Eyeblink Startle Response (recorded via EMG sensors) will be quantified as the peak blink amplitude relative to the onset of an auditory startle probe during blocks with predictable shocks, unpredictable shocks, and no threat of shock. The Eyeblink Startle Response during unpredictable shock threat vs. no shock threat will be the primary contrast of interest.

2 secondary outcomes

Delta Power
Time frame: Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up
Delta Intertrial Phase Coherence
Time frame: Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 5 Aug 2026.

Related trials for Cannabis Use Disorder, Severe

Active, not recruitingPhase 2
Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study
Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
Not yet recruitingPhase 3
Tirzepatide in the Treatment of Cannabis Use Disorder
Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
Recruiting
Cannabis and Processing Emotions Study
Cannabis Use Disorder, Severe
Active, not recruiting
Cannabis Use Disorder Treatment Study
Cannabis Use Disorder, Mild, Cannabis Use Disorder, Moderate

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Late Positive Potential (time frame: Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07746440.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2026; AzTrials last refreshed its copy on 7 Nov 2026.